-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Amgen's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$25.98 B | $26.32 B | $28.19 B | $33.42 B | $36.75 B |
| Cost of Revenue |
|
$6.45 B | $6.41 B | $8.42 B | $12.86 B | $6.42 B |
| Gross Profit |
|
$19.53 B | $19.92 B | $19.78 B | $20.57 B | $30.33 B |
| Research & Development |
|
$4.82 B | $4.43 B | $4.78 B | $5.96 B | $7.27 B |
| Selling,General & Administrative |
|
$5.37 B | $5.41 B | $6.18 B | $7.10 B | $7.05 B |
| Operating Expense |
|
$11.89 B | $10.35 B | $11.84 B | $13.31 B | $15.44 B |
| Operating Income |
|
$7.64 B | $9.57 B | $7.90 B | $7.26 B | $14.89 B |
| Net Income |
|
$5.89 B | $6.55 B | $6.72 B | $4.09 B | $7.71 B |
Amgen's Assets vs Liabilities & Equity
Amgen's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$8.04 B | $9.31 B | $10.94 B | $11.97 B | $9.13 B |
| Inventories |
|
$4.09 B | $4.93 B | $9.52 B | $7.00 B | $6.23 B |
| Total Current Assets |
|
$19.39 B | $22.19 B | $30.33 B | $29.03 B | $29.06 B |
| Property,Plant and Equipment |
|
$5.18 B | $5.43 B | $6.59 B | $6.54 B | $7.91 B |
| Goodwill |
|
$14.89 B | $15.53 B | $18.63 B | $18.64 B | $18.68 B |
| Total Assets |
|
$61.17 B | $65.12 B | $97.15 B | $91.84 B | $90.59 B |
| Total Liabilities |
|
$54.47 B | $61.46 B | $90.92 B | $85.96 B | $81.93 B |
| Retained Earnings |
|
-$24.60 B | -$28.62 B | -$26.55 B | -$27.59 B | - |
| Total Shareholder Equity |
|
$6.70 B | $3.66 B | $6.23 B | $5.88 B | $8.66 B |
| Common Stock |
|
$32.10 B | $32.51 B | $33.07 B | $33.53 B | $8.66 B |
Amgen's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$3.40 B | $3.42 B | $4.07 B | $5.59 B | - |
| Dividends Payout |
|
-$4.01 B | -$4.20 B | -$4.56 B | -$4.83 B | - |
| Capital Expenditures (Capex) |
|
-$880.00 M | -$936.00 M | -$1.11 B | -$1.10 B | -$1.86 B |
| Free Cash Flow (FCF) |
|
$8.38 B | $8.79 B | $7.36 B | $10.39 B | $8.10 B |
Amgen's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$19.53 B | $19.92 B | $19.78 B | $20.57 B | $30.33 B |
| Gross Profit Margin (%) |
|
75.16% | 75.66% | 70.15% | 61.53% | 70.80% |
| Operating Income |
|
$7.64 B | $9.57 B | $7.90 B | $7.26 B | $14.89 B |
| Operating Income Margin (%) |
|
29.40% | 36.34% | 28.01% | 21.71% | 29.06% |
| Net Income |
|
$5.89 B | $6.55 B | $6.72 B | $4.09 B | $7.71 B |
| Net Income Margin (%) |
|
22.68% | 24.89% | 23.83% | 12.24% | 20.99% |
| EBITDA |
|
$11.30 B | $12.17 B | $14.80 B | $13.36 B | $17.13 B |
| EBITDA Margin (%) |
|
43.48% | 46.23% | 52.50% | 39.96% | 43.12% |
Amgen's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
87.96% | 178.97% | 107.78% | 69.59% | - |
| Return on Assets (ROA) |
|
9.63% | 10.06% | 6.91% | 4.45% | - |
| Debt to Equity |
|
497.15% | 1,063.78% | 1,036.79% | 1,022.61% | 630.68% |
| Debt to total asset |
|
54.46% | 59.80% | 66.51% | 65.44% | 60.28% |
| Enterprise value to revenue |
|
5.94 | 6.56 | 7.37 | 5.66 | 0.00 |
| Enterprise value to EBITDA |
|
13.65 | 14.18 | 14.04 | 14.16 | 0.00 |
| Enterprise value |
|
$154.22 B | $172.62 B | $207.76 B | $189.13 B | - |
| Tax Rate (%) |
|
12.06% | 10.81% | 14.49% | 11.26% | 14.09% |
Frequently Asked Questions
